991. Deputy Colm Burke asked the Minister for Health the person within the HSE who decides if a product is experimental in respect of the treatment abroad scheme; the criteria that this decision maker uses to decide such and the definitions applied to experimental treatments; if the relevant decision makers have the expertise to review drugs for complex conditions; if the existing reimbursement list is referred to in making reimbursement decisions or whether European Medicines Agency approval is deemed to be the overriding proof of clinical safety; and if he will make a statement on the matter. [37831/22]

Summary

991. Deputy Colm Burke asked the Minister for Health the person within the HSE who decides if a product is experimental in respect of the treatment abroad scheme; the criteria that this decision maker uses to decide such and the definitions applied to experimental treatments; if the relevant decision makers have the expertise to review drugs for complex conditions; if the existing reimbursement list is referred to in making reimbursement decisions or whether European Medicines Agency approval is deemed to be the overriding proof of clinical safety; and if he will make a statement on the matter. [37831/22]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Healthcare Policy

  xml · EN · 12 July 2022

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.